Mitsubishi UFJ Trust & Banking Corp lessened its holdings in shares of Chemed Co. (NYSE:CHE - Free Report) by 92.3% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 136 shares of the company's stock after selling 1,623 shares during the quarter. Mitsubishi UFJ Trust & Banking Corp's holdings in Chemed were worth $72,000 as of its most recent filing with the Securities and Exchange Commission (SEC).
Other hedge funds have also recently modified their holdings of the company. Raymond James Financial Inc. bought a new position in shares of Chemed in the fourth quarter worth about $42,023,000. HighTower Advisors LLC raised its stake in Chemed by 78.0% during the 3rd quarter. HighTower Advisors LLC now owns 3,730 shares of the company's stock worth $2,246,000 after acquiring an additional 1,634 shares during the period. XTX Topco Ltd lifted its holdings in Chemed by 111.5% during the third quarter. XTX Topco Ltd now owns 2,843 shares of the company's stock valued at $1,709,000 after purchasing an additional 1,499 shares in the last quarter. Geode Capital Management LLC boosted its position in shares of Chemed by 4.9% in the third quarter. Geode Capital Management LLC now owns 335,443 shares of the company's stock worth $201,820,000 after purchasing an additional 15,791 shares during the period. Finally, Signal Advisors Wealth LLC increased its stake in shares of Chemed by 60.7% in the fourth quarter. Signal Advisors Wealth LLC now owns 4,995 shares of the company's stock worth $2,647,000 after purchasing an additional 1,886 shares in the last quarter. Institutional investors own 95.85% of the company's stock.
Wall Street Analysts Forecast Growth
A number of research analysts recently weighed in on CHE shares. StockNews.com upgraded shares of Chemed from a "hold" rating to a "buy" rating in a research note on Friday, March 7th. Royal Bank of Canada boosted their price objective on Chemed from $633.00 to $667.00 and gave the company an "outperform" rating in a research report on Friday, March 14th.
Check Out Our Latest Stock Analysis on CHE
Insiders Place Their Bets
In other news, CEO Kevin J. Mcnamara sold 1,000 shares of the firm's stock in a transaction that occurred on Monday, March 31st. The stock was sold at an average price of $615.33, for a total value of $615,330.00. Following the completion of the sale, the chief executive officer now directly owns 101,679 shares of the company's stock, valued at $62,566,139.07. This trade represents a 0.97 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Corporate insiders own 3.32% of the company's stock.
Chemed Price Performance
Shares of CHE stock traded down $22.01 during mid-day trading on Monday, hitting $575.33. The company had a trading volume of 162,812 shares, compared to its average volume of 96,001. Chemed Co. has a 52-week low of $512.12 and a 52-week high of $632.22. The stock's 50 day moving average price is $580.26 and its 200-day moving average price is $567.90. The company has a market capitalization of $8.42 billion, a P/E ratio of 29.07, a P/E/G ratio of 2.15 and a beta of 0.49.
Chemed Dividend Announcement
The firm also recently disclosed a quarterly dividend, which was paid on Friday, March 14th. Shareholders of record on Monday, February 24th were given a dividend of $0.50 per share. The ex-dividend date was Monday, February 24th. This represents a $2.00 annualized dividend and a yield of 0.35%. Chemed's dividend payout ratio (DPR) is currently 10.05%.
Chemed Company Profile
(
Free Report)
Chemed Corporation provides hospice and palliative care services to patients through a network of physicians, registered nurses, home health aides, social workers, clergy, and volunteers primarily in the United States. The company operates in VITAS and Roto-Rooter segments. It offers plumbing, drain cleaning, excavation, water restoration, and other related services to residential and commercial customers through company-owned branches, independent contractors, and franchisees.
See Also

Before you consider Chemed, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Chemed wasn't on the list.
While Chemed currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.